The positive Phase III data de-risks Ris-Rez as a key pipeline asset for GSK, supporting its oncology growth strategy. Traders should watch for upcoming data from the global EMBOLD Sarcoma-202 trial and potential regulatory submissions in China and the US, which could be catalysts for further upside.
Drug in focus
GSK drug pipeline →risvutatug rezetecan
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- ~3-4 years for global approval; China approval possible ~12-18 months post Hansoh filing
- Next catalyst
- None dated
What to watchThe ARTEMIS-008 Phase 3 win in China (positive OS vs topotecan in SCLC) is a major validation of the B7-H3 ADC mechanism, but for GSK investors the real catalyst is the global Phase 3 readout (primary completion now Oct 2027). Watch for China NDA filing timing and any early data from the ongoing EMBOLD/ARTEMIS expansion trials in prostate, NSCLC, and other solid tumors. With ~$1-2B peak sales potential (ex-China), risvutatug rezetecan is a meaningful but non-binary asset within GSK's broader pipeline.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $53.71entry
- T+1 · 4mo ago −0.91%α +0.63% · $53.22
- T+5 · 4mo ago −4.10%α −6.37% · $51.51
- T+20 · 3mo ago −3.05%α −6.43% · $52.07
- T+60 · 27d ago −6.87%α −11.22% · $50.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK's licensor Hansoh Pharma announced positive Phase III results for risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma, meeting the primary endpoint of progression-free survival. This is the second positive Phase III readout for Ris-Rez, following recent pivotal data in small-cell lung cancer, and strengthens the asset's late-stage profile. The news is a positive pipeline catalyst for GSK's oncology program, though Ris-Rez is still in development and not yet generating revenue, limiting near-term financial impact.
Key Facts
- Hansoh Pharma's ARTEMIS-011 Phase III trial of Ris-Rez met its primary endpoint of progression-free survival in relapsed osteosarcoma.
- Ris-Rez is the only B7-H3-targeted ADC to deliver positive Phase III outcomes across multiple tumor types (osteosarcoma and SCLC).
- GSK holds exclusive global rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
- Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma and relapsed/refractory extensive-stage SCLC.
- GSK is advancing a global Phase Ib/II trial (EMBOLD Sarcoma-202) of Ris-Rez in sarcomas, including osteosarcoma.
Financial Impact
No financial figures disclosed. Ris-Rez is an investigational asset with no current revenue; positive Phase III data supports its pipeline value and potential future regulatory submissions.
Risk Factors
- Ris-Rez is still in clinical development and faces regulatory and commercial risks.
- The osteosarcoma indication is a rare cancer with a small patient population, limiting peak revenue potential.
- Competition from other B7-H3-targeted therapies could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006951 |
| Document: 0001654954-26-006951-index-headers.html | 0001654954-26-006951 |
| Document: 0001654954-26-006951-index.html | 0001654954-26-006951 |
| Document: 0001654954-26-006951.txt | 0001654954-26-006951 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers